Repatha vs Losartan: Switching Between Them Explained

What Are These Two Drugs Actually Treating?

Repatha and losartan are not competing drugs. Repatha is a PCSK9 inhibitor that reduces LDL cholesterol, while losartan is an angiotensin II receptor blocker (ARB) that reduces blood pressure. Asking whether one is "better" than the other is like comparing insulin to a beta-blocker: both reduce cardiovascular risk, but through entirely separate mechanisms and for different indications.

Repatha (Evolocumab): A PCSK9 Inhibitor

Evolocumab is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9), preventing it from degrading LDL receptors on hepatocytes. With more LDL receptors available, the liver clears more LDL-C from the blood. The FDA approved evolocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statin therapy. [1]

The standard dose is 140 mg subcutaneously every two weeks, or 420 mg once monthly via a prefilled autoinjector or on-body infusor device. Evolocumab does not lower blood pressure. It has no antihypertensive activity.

Losartan: An Angiotensin II Receptor Blocker

Losartan was the first ARB approved in the United States (1995). It blocks the AT1 receptor, preventing angiotensin II from causing vasoconstriction and aldosterone release, which directly reduces systemic vascular resistance and blood pressure. Typical adult doses range from 25 mg to 100 mg orally once daily. Losartan has no direct lipid-lowering mechanism. Some early animal studies suggested modest cholesterol-independent vascular effects, but no major human trial has demonstrated clinically meaningful LDL reduction from losartan.

Head-to-Head Evidence: Does Any Exist?

No randomized controlled trial has directly compared evolocumab to losartan for the same cardiovascular endpoint. This makes clinical sense: guideline bodies such as the ACC/AHA do not position these agents as alternatives for the same indication. The relevant trials tested each drug against placebo or an active comparator within its own therapeutic category.

FOURIER: The Evidence Base for Evolocumab

The FOURIER trial (NCT01764633) randomized 27,564 patients with established ASCVD and LDL-C of at least 70 mg/dL on optimized statin therapy to evolocumab 140 mg every two weeks (or 420 mg monthly) vs. Placebo. At a median follow-up of 2.2 years, evolocumab reduced LDL-C by 59% from a median baseline of 92 mg/dL down to 30 mg/dL. The primary endpoint, a composite of cardiovascular death, myocardial infarction, stroke, coronary revascularization, or unstable angina hospitalization, occurred in 11.3% of the evolocumab group vs. 12.6% in the placebo group (HR 0.85; 95% CI 0.79 to 0.92; P<0.001). [1] That translates to a 15% relative risk reduction.

Sabatine et al. Reported: "Inhibition of PCSK9 with evolocumab on a background of statin therapy lowered LDL cholesterol levels by 59% and reduced the risk of cardiovascular events." [1]

LIFE: The Evidence Base for Losartan

The LIFE trial (Lancet 2002) randomized 9,193 hypertensive patients with left ventricular hypertrophy to losartan-based or atenolol-based antihypertensive therapy. Both arms achieved similar blood pressure reductions (about 30/16 mmHg from baseline). The primary composite endpoint (cardiovascular death, stroke, or myocardial infarction) occurred in 11.1% of the losartan group vs. 12.5% in the atenolol group (HR 0.87; 95% CI 0.77 to 0.98; P=0.021), a 13% relative risk reduction. [2] The benefit was especially pronounced for stroke reduction: losartan reduced fatal and non-fatal stroke by 25% relative to atenolol.

The LIFE investigators noted: "Losartan prevents more cardiovascular morbidity and death than atenolol for a similar reduction in blood pressure and is better tolerated." [2]

Why Comparing These Trial Outcomes Directly Is Misleading

FOURIER enrolled patients with established ASCVD at high baseline LDL. LIFE enrolled hypertensive patients selected for LV hypertrophy on ECG. The populations, comparators, endpoints, and biological targets are all different. A numeric comparison of their hazard ratios tells you almost nothing clinically useful. What both trials do confirm is that each drug reduces MACE within its own mechanistic domain, and a patient with both elevated LDL and hypertension may reasonably receive both.

Mechanism Deep Dive: LDL Pathway vs. Renin-Angiotensin-Aldosterone System

Understanding the difference in pathways clarifies why these drugs are not interchangeable.

The PCSK9 Pathway and Cholesterol Clearance

PCSK9 binds to the LDL receptor (LDLR) on hepatocyte surfaces after the LDLR internalizes LDL particles. Normally, PCSK9 directs the LDLR to lysosomal degradation, reducing LDLR recycling back to the cell surface. Evolocumab neutralizes free PCSK9 in plasma, allowing 60 to 80% more LDLR to recycle, dramatically increasing hepatic LDL clearance. This mechanism is entirely independent of blood pressure regulation. [3]

Patients with loss-of-function mutations in PCSK9 naturally carry LDL-C levels 15 to 28% lower than the general population and show a lifetime ASCVD risk reduction of roughly 88%, a finding that supported the pharmacological rationale for PCSK9 inhibitors. [4]

The Renin-Angiotensin-Aldosterone System and Blood Pressure

Losartan blocks the angiotensin II type 1 receptor. This prevents angiotensin II from triggering vasoconstriction, sodium and water retention, and aldosterone secretion. Losartan also has a secondary uricosuric effect (lowering serum uric acid) not shared by other ARBs, which may offer a minor cardiovascular benefit in patients with gout. [5] This mechanism has no lipid-lowering consequence.

The 2018 ACC/AHA Blood Cholesterol Guideline and the 2023 ESC/EAS Guideline for dyslipidaemia management both position ARBs as antihypertensive agents and PCSK9 inhibitors as lipid-lowering agents; neither guideline treats them as alternatives to each other. [6]

When Would a Clinician Consider "Switching"?

The most common clinical scenario where a provider might discuss switching involves a patient on evolocumab who develops financial barriers to continuing the biologic, or a patient on losartan whose cardiovascular risk reclassification reveals a simultaneously elevated LDL that also needs treatment. Neither scenario is a true pharmacological substitution.

Scenario 1: Patient Stopping Repatha Due to Cost

Evolocumab carries a list price near $550 per month, though manufacturer patient assistance programs (PAP) may reduce out-of-pocket cost to zero for qualifying patients. When a patient discontinues evolocumab due to cost, the clinician does not replace it with losartan. The replacement options are:

• Maximizing statin dose (e.g., rosuvastatin 40 mg daily)
• Adding ezetimibe 10 mg daily (additional 18 to 20% LDL-C reduction)
• Switching to inclisiran (two injections per year; may have different formulary coverage)
• Applying for manufacturer or state PAP for evolocumab

Losartan would not be prescribed in this context unless the patient also had hypertension requiring an ARB.

Scenario 2: Patient Stopping Losartan and Reclassified for PCSK9 Inhibitor

A hypertensive patient who achieves blood pressure control and is subsequently reclassified as very high ASCVD risk might be identified as a candidate for evolocumab. This is not a "switch" from losartan to evolocumab; it is the addition of a new agent in a new drug class. The two drugs can run concurrently without pharmacokinetic interaction. Because evolocumab is a large biologic and losartan is a small molecule metabolized primarily via CYP2C9, there is no known drug interaction between them. [7]

Scenario 3: Combination Use in High-Risk Patients

Patients most likely to receive both evolocumab and losartan simultaneously are those with:

1. Established ASCVD (prior MI, stroke, or symptomatic PAD)
2. LDL-C above 70 mg/dL despite maximally tolerated statin therapy
3. Hypertension (office blood pressure above 130/80 mmHg per 2017 ACC/AHA guidelines)
4. Possible concurrent CKD, where losartan also provides renoprotective benefit

The ACC/AHA 2019 Primary Prevention Guideline explicitly recommends PCSK9 inhibitor consideration for very high-risk patients with LDL-C at 70 mg/dL or higher on maximally tolerated therapy, independent of blood pressure control status. [8] Achieving goal blood pressure with losartan does not remove the indication for evolocumab in these patients.

Safety Profiles: Where They Differ

Evolocumab Adverse Effects

Evolocumab is generally well-tolerated in clinical trials. In FOURIER, the most common adverse effects were injection site reactions (occurring in 2.1% vs. 1.6% placebo), nasopharyngitis, and upper respiratory infections. Rates of new-onset diabetes, myalgias, and liver enzyme elevations were not statistically different from placebo. [1] Neurocognitive concerns raised in early post-marketing reports were tested prospectively in the EBBINGHAUS sub-study (N=1,974), which showed no significant difference in cognitive function between evolocumab and placebo groups over 19 months of follow-up. [9]

Losartan Adverse Effects

Losartan's most clinically significant adverse effect is hyperkalemia, particularly in patients with CKD, diabetes, or concurrent use of potassium-sparing diuretics or ACE inhibitors. Serum potassium monitoring is standard practice. Losartan, like all ARBs, is absolutely contraindicated in pregnancy (Category D/X depending on trimester) due to fetal renal toxicity. [10] Unlike ACE inhibitors, losartan does not cause the bradykinin-mediated dry cough, making it a preferred ARB for ACE-inhibitor-intolerant patients.

Angioedema may rarely occur with ARBs but at a substantially lower rate than with ACE inhibitors. Patients with prior ACE inhibitor-associated angioedema should still use ARBs with caution. [10]

Comparing Tolerability Side by Side

Evolocumab has essentially no oral tolerability issues (it is a subcutaneous injection). Losartan's tolerability burden is primarily the need for electrolyte and renal function monitoring, plus the pregnancy contraindication. Neither drug causes the same adverse effects as the other, which again underscores that they are not alternatives.

Guideline Positioning: What ACC/AHA and ESC Actually Recommend

Current major guidelines are explicit on where each drug belongs in the treatment algorithm.

ACC/AHA 2018 Blood Cholesterol Guideline on PCSK9 Inhibitors

The 2018 ACC/AHA Blood Cholesterol Guideline grants a Class I recommendation (Level of Evidence A) for PCSK9 inhibitor therapy in patients with clinical ASCVD who are on maximally tolerated statin therapy and have LDL-C at 70 mg/dL or higher, and a Class IIa recommendation for patients with LDL-C at 70 mg/dL or higher on combination statin plus ezetimibe therapy. [6]

ACC/AHA 2017 Hypertension Guideline on ARBs

The 2017 ACC/AHA Hypertension Guideline recommends ARBs (including losartan) as first-line agents for hypertension in patients with CKD, heart failure with reduced ejection fraction, or diabetes with microalbuminuria. [11] These guidelines do not cross-reference PCSK9 inhibitors as antihypertensive alternatives, nor do they suggest ARBs as lipid-lowering agents.

Practical Decision Framework for Clinicians

When a patient asks about switching between Repatha and losartan, a structured three-question approach helps clarify management:

Question 1: What is the indication for the current drug? If the patient is on evolocumab for LDL-C control, the clinical problem is dyslipidemia. Losartan does not treat dyslipidemia. If the patient is on losartan for hypertension, the problem is elevated blood pressure. Evolocumab does not treat hypertension.

Question 2: Has the underlying indication resolved or changed? If evolocumab has brought LDL-C to target (below 55 mg/dL for very high-risk patients per ESC 2019 guidelines), the conversation becomes whether to de-escalate to statin plus ezetimibe, not whether to add losartan. If losartan has controlled blood pressure to goal, the conversation becomes whether the patient also needs lipid therapy, not whether to add evolocumab unless LDL remains elevated.

Question 3: Is there a financial or tolerability reason driving the question? Cost-driven discontinuation of evolocumab requires a lipid-lowering alternative, not an antihypertensive switch. Explore PAP enrollment, inclisiran dosing schedule, or ezetimibe combination before assuming coverage is unavailable.

Cost and Access Considerations

The financial gap between these two agents is substantial. Generic losartan 50 mg costs approximately $4, $10 per month at most major pharmacies. Evolocumab carries a list price near $550, $600 monthly, though the net price after insurer rebates is typically lower, and Amgen's PAP program (Repatha SupportPlus) may provide the drug at no cost to eligible uninsured or underinsured patients. [12]

The ICER 2022 value assessment for PCSK9 inhibitors concluded that evolocumab is cost-effective at prices around $4,500, $7,500 per year (approximately $375, $625 per month) when applied to very high-risk ASCVD patients, placing current prices near the upper bound of cost-effectiveness thresholds. [13]

Patients who cannot afford evolocumab long-term may achieve LDL-C reductions of 50 to 65% from baseline using high-intensity rosuvastatin 40 mg plus ezetimibe 10 mg daily, at a combined cost under $20/month for most generics.

Key Takeaway for Patients

These two drugs are not substitutes for each other, and no published trial has tested switching one for the other as a clinical strategy. Your cardiologist or primary care physician prescribes each for a specific, different reason. If you have both high LDL and high blood pressure, you might need both at the same time. If cost is a concern with evolocumab, contact the Amgen PAP at 1-844-REPATHA or ask your provider about inclisiran or intensified statin-ezetimibe therapy as lipid-lowering alternatives.